Catalent | CTLT - Sales Revenues

Catalent reported $1.02B in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
Agilent USD 1.66B 30M Dec/2023
AstraZeneca USD 12.02B 532M Dec/2023
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Bruker USD 854.5M 111.7M Dec/2023
Catalent USD 1.02B 42M Dec/2023
Centene USD 40.41B 950M Mar/2024
Charles River Laboratories USD 1.01B 13.15M Dec/2023
Cigna USD 51.11B 2.04B Dec/2023
Danaher USD 5.8B 605M Mar/2024
Dentsply International USD 1.01B 65M Dec/2023
Elevance Health 42.3B 154M Mar/2024
Eli Lilly USD 9.35B 145.2M Dec/2023
Glaxosmithkline GBP 8.05B 95M Dec/2023
Hologic USD 1.01B 67.8M Dec/2023
Humana USD 29.33B 3.6B Mar/2024
Illumina USD 1.12B 3M Dec/2023
Intuitive Surgical USD 1.89B 38.3M Mar/2024
IQVIA Holdings USD 3.87B 132M Dec/2023
J&J USD 21.38B 15M Mar/2024
Laboratory Of America USD 3.18B 146.7M Mar/2024
Lonza CHF 3.64B 561M Dec/2023
McKesson USD 80.9B 3.68B Dec/2023
Merck EUR 14.76B 9.54B Mar/2024
Merck USD 15.8B 1.17B Mar/2024
Mettler Toledo International USD 934.99M 7.47M Dec/2023
Novartis USD 11.83B 54M Mar/2024
Pfizer USD 14.25B 1.02B Dec/2023
Quest Diagnostics USD 2.37B 82M Mar/2024
Repligen USD 155.74M 14.55M Dec/2023
Revvity USD 695.9M 25.16M Dec/2023
Roche Holding CHF 28.94B 842M Dec/2023
Supernus Pharmaceuticals USD 164.31M 10.43M Dec/2023
Thermo Fisher Scientific USD 10.34B 546M Mar/2024
UnitedHealth 99.8B 5.37B Mar/2024
Waters USD 819.47M 107.78M Dec/2023
West Pharmaceutical Services USD 695.4M 36.6M Mar/2024